Horizon Blue Cross Blue Shield of New Jersey
08/31/2026 | Press release | Distributed by Public on 08/31/2026 05:12
Q3 2026 Classic Formulary Changes
Horizon's Pharmacy and Therapeutics (P&T) Committee meets quarterly to review new drugs, drug classes, clinical indications, therapeutic advantages, chemical entities and safety information to help ensure that our formularies encourage the use of safe, effective and affordable drugs by our members.
Below are the formulary changes determined at the third quarter 2026 P&T Committee meeting held in August 2026.
Move to Preferred Status
| Brand Name | Generic Name | Prior Authorization (Y/N) | Effective Date |
| Fiasp® Pumpcart Cartridge | insulin aspart 100 units/mL, 1.6 mL | Y | 9/1/2026 |
| N/A | sodium fluoride/potassium nitrate gel 1.1%/5% | N | 11/1/2026 |
Move to Non-Preferred Status
| Brand Name | Generic Name | Prior Authorization (Y/N) | Effective Date |
| Valtya™ 1/50 tablet | ethynodiol diacetate 1 mg / ethinyl estradiol 50 mcg tablet | N | 11/1/2026 |
| Velivet® | desogestrel/ethinyl estradiol triphasic tablet pack | N | 11/1/2026 |
| N/A | hydrocodone polistirex/chlorpheniramine polistirex ER suspension 10 mg/8 mg per 5 mL | Y | 11/1/2026 |
| N/A | phenelzine sulfate tablet 15 mg | N | 11/1/2026 |
| N/A | cromolyn sodium ophthalmic solution 4% | N | 11/1/2026 |
| Proctocort ® & Hydrocort | hydrocortisone perianal cream 1% | N | 11/1/2026 |
Move to Non-Formulary Status
| Brand Name | Generic Name | Prior Authorization (Y/N) | Effective Date |
| N/A | Temozolomide* | Y | 11/1/2026 |
| N/A | Fingolimod* | N | 11/1/2026 |
| N/A | Everolimus* | Y | 11/1/2026 |
| N/A | Abiraterone* | Y | 11/1/2026 |
| N/A | Dalfampridine* | N | 11/1/2026 |
| N/A | Capecitabine* | Y | 11/1/2026 |
| N/A | Dimethyl fumarate* | Y | 11/1/2026 |
| N/A | Droxidopa* | Y | 11/1/2026 |
*All current and future non-CivicaScript®, non-biologic products where a CivicaScript® alternative is available will move to non-formulary; CivicaScript® medications will be available exclusively through SortPak Pharmacy to help ensure consistent access and pricing
Remains in Non-Formulary Status
| Brand Name | Generic Name | Prior Authorization (Y/N) | Effective Date |
| Pivya™ | Pivmecillinam 185 mg tablets | Y | 9/1/2026 |
| Kygevvi™ | doxecitine/doxribtimine 2g/2g powder for oral solution | Y | 9/1/2026 |
| Voyxact™ | sibeprenlimab-szsi 400 mg/2mL injection | Y | 9/1/2026 |
| Cardamyst® | etripamil 70 mg nasal solution | Y | 9/1/2026 |
| Myqorzo® | Aficamten 5, 10, 15, 20 mg tablets | Y | 9/1/2026 |
| Zycubo™ | copper histidinate 2.9 mg/vial | Y | 9/1/2026 |
| Yuviwel™ | Navepegritide 1.3, 2.8, 5.5 mg injection | Y | 9/1/2026 |
| Arynta™ | lisdexamfetamine oral solution | Y | 9/1/2026 |
| Sdamlo™ | Amlodipine 2.5, 5, 10 mg oral solution | Y | 9/1/2026 |
| Subvenite™ | lamotrigine 10 mg/mL oral suspension | Y | 9/1/2026 |
| Lasix® ONYU | furosemide 80 mg/2.67 mL injection | Y | 9/1/2026 |
| Vybrique™ | sildenafil 25,50,75,100 mg oral film | Y | 9/1/2026 |
| Yuvezzi™ | brimonidine/ carbacol (0.1%/2.75%) ophthalmic solution | N | 9/1/2026 |
| Ontralfy™ | tizanidine hc 2mg/5mLl oral solution | Y | 9/1/2026 |
| Desmoda™ | Desmopressin 0.05mg/mL oral solution | Y | 9/1/2026 |
| Rezenopy™ | naloxone 10 mg nasal spray | Y | 9/1/2026 |
| N/A | glipizide 15mg tablets | Y | 9/1/2026 |
| Eurax ® | Crotamiton 10% cream | Y | 9/1/2026 |
| N/A | tolmetin 200mg tablets | Y | 9/1/2026 |
| N/A | buspirone 2.5mg and 12.5mg | Y | 9/1/2026 |
| N/A | duloxetine EC pellets 80mg, 90mg, 120mg | Y | 9/1/2026 |
| N/A | tapentadol 20mg/ml solution | Y | 9/1/2026 |
| N/A | benzonatate 150mg capsule | Y | 9/1/2026 |
| Dexlyt™ 0.25mg tablet | dexamethasone 0.25mg tablet | Y | 9/1/2026 |
| N/A | fenoprofen 200mg capsule | Y | 9/1/2026 |
| N/A | dronabinol 5mg/ml solution | Y | 9/1/2026 |
| Ursolign™ | ursodiol capsule 150mg | Y | 9/1/2026 |
Move to Medical Status
| Brand Name | Generic Name | Prior Authorization (Y/N) | Effective Date |
| CeQur Simplicity® | Insulin injection device, starter kit, and accessories including inserters | N | 11/1/2026 |
| InPen® | Injection Device for Insulin | N | 10/1/2026 |
| NovoPen Echo® | Injection Device for Insulin | N | 11/1/2026 |
| Autopen® | Injection Device for Insulin | N | 10/1/2026 |
| BD Pen and BD Pen Mini™ | Injection Device for Insulin | N | 10/1/2026 |
This document contains prescription brand name drugs that are registered marks or trademarks of pharmaceutical manufacturers that are not affiliated with either Horizon Blue Cross Blue Shield of New Jersey or the Blue Cross Blue Shield Association.
Published on: August 31, 2026, 01:05 a.m. ET
Last updated on: August 31, 2026, 07:06 a.m. ET
Horizon Blue Cross Blue Shield of New Jersey published this content on August 31, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 31, 2026 at 11:12 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]